Real-World Studies
Microfluidic Drug Screening Correlates With Pediatric ALL Outcomes
Williams et alNature Biomedical Engineering

Developing effective treatment strategies for high-risk pediatric acute lymphoblastic leukemia (ALL) increasingly relies on personalized approaches, yet few functional assays are clinically actionable or readily integrated into pathology settings. To address this gap, researchers developed GradientScreen, a microfluidic combination drug screening assay that generates overlapping drug gradients to characterize drug synergy and efficacy in a ratiometric framework.
Using partial least squares regression, the study showed that combination response metrics derived from the platform correlate with minimal residual disease (MRD) following treatment initiation as well as later clinical end-points under standard pediatric ALL protocols. The authors further demonstrated that the system could be used to evaluate response to experimental therapeutic regimens in patients refractory to standard treatment. The platform is presented as an assay with potential to integrate into clinical pathology workflows to identify difficult-to-treat ALL patients and screen alternative treatment regimens at initial diagnosis.
Key Takeaways
- Combination response metrics from the microfluidic assay correlated with both minimal residual disease following treatment initiation and later clinical end-points in pediatric acute lymphoblastic leukemia.
- The assay demonstrated utility in evaluating response to experimental therapeutic regimens in patients who did not respond to standard therapy.
Read the original sourceNature Biomedical Engineering
